Replies to post #205384 on Biotech Values

[DewDiligence]

CERC +19% on ALKS’ coattails (eom).

[north40000]

One take on ALKS:

http://marketexclusive.com/heres-take-alkermes-plc-nasdaqalkss-latest-hit/34712/?icd1

"Alkermes Plc (NASDAQ:ALKS) just demonstrated why it’s so important to monitor through to completion in the biotech space. The company reported the failure of two phase III trials in its lead depression asset in February this year, and basically collapsed overnight. There was a hint of efficacy however, in the second of the two trials, albeit not enough to register as statistically significant, and Alkermes *** pounced on this hint and expanded into a third pivotal. This is something we’ve seen companies do time and time again, and it’s also something that many analysts would take a look at and denounce as an attempt to stem negative sentiment post data release....[more]"

[DewDiligence]

ALKS trading flat despite nominally positive phase-3 in schizophrenia:

https://finance.yahoo.com/news/alkermes-announces-positive-preliminary-topline-200000153.html

ALKS 3831 is intended to be as efficacious as Zyprexa with less weight gain, but the ENLIGHTEN-1 study didn’t show that. A separate study, ENLIGHTEN-2, will directly test weight gain of ALKS 3831 vs Zyprexa with results expected in 2018.